Evidence map›Paper›PMID 24378418›Full record

ArticleJAMA neurology2014

Associations between serum cholesterol levels and cerebral amyloidosis.

Bruce Reed, Sylvia Villeneuve, Wendy Mack, Charles DeCarli, Helena C Chui, William Jagust

Open access · greenAbstract readMulticenter Study
In one paragraph

Article in JAMA neurology, 2014. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 152 papers, 5 of them syntheses that pooled it.

0numbers the graph read from it
0cells of the map it votes in
152citing papers in PubMed, 5 pooled it
10.9field-weighted citation impact, top 1% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

152 citing papers in PubMed, 5 syntheses or guidelines pooled it, 263 citations in OpenAlex.

  1. Pooled it
  2. Pooled it
  3. Pooled it
  4. Pooled it
  5. Omega-3 fatty acids for the treatment of dementia.The Cochrane database of systematic reviews · 2016
    Pooled it
  6. Trial
  7. Article
  8. Article
  9. Article
  10. Article
  11. Article
  12. Article
  13. Review
  14. Article
  15. Association of type 2 diabetes treatment status with in vivo biomarkers of Alzheimer's disease.Alzheimer's & dementia : the journal of the Alzheimer's Association · 2026
    Article
  16. Observational
  17. Article
  18. Article
  19. Article
  20. Article

92 more citing papers are in PubMed but not listed here.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

6 authors at 3 institutions in 1 country.

Bruce ReedUniversity of California, Davis.
Sylvia VilleneuveUniversity of California, Berkeley.
Wendy MackUniversity of Southern California, Los Angeles.
Charles DeCarliUniversity of California, Davis.
Helena C ChuiUniversity of Southern California, Los Angeles.
William JagustUniversity of California, Berkeley.
University of California, Berkeley · USUniversity of California, Davis · USUniversity of Southern California · US

Funding

VASCULAR RISK AND COGNITIVE STATUS IN A LATINO POPULATIONP50AG005142 · NIA · UNIVERSITY OF SOUTHERN CALIFORNIA · PI ARANDA, MARIA P. · 1985 to 2019
$41.0M
UC Davis Alzheimer's Disease Core CenterP30AG010129 · NIA · UNIVERSITY OF CALIFORNIA DAVIS · PI DECARLI, CHARLES · 1991 to 2020
$28.3M
The Aging Brain: Vasculature, Ischemia, and BehaviorP01AG012435 · NIA · UNIVERSITY OF SOUTHERN CALIFORNIA · PI REED, BRUCE · 1994 to 2012
$26.4M
Neural and Biochemical Mechanisms of Cognitive AgingR01AG034570 · NIA · UNIVERSITY OF CALIF-LAWRENC BERKELEY LAB · PI William J. Jagust · 2009 to 2026
$12.0M
Brain pathologies, reserve and cognition in aging and dementiaR01AG031563 · NIA · UNIVERSITY OF CALIFORNIA AT DAVIS · PI Evan Fletcher, SARAH E TOMASZEWSKI-FARIAS · 2009 to 2026
$8.9M
NRF2 Anti-Oxidant Systems and White Matter HyperintensitiesR01AG042292 · NIA · UNIVERSITY OF CALIFORNIA AT DAVIS · PI DECARLI, CHARLES, SHARP, FRANK R · 2013 to 2017
$3.0M
NIA NIH HHS AG034570NIA NIH HHS P01 AG012435NIA NIH HHS P01 AG12435NIA NIH HHS P30 AG010129NIA NIH HHS P30 AG10129NIA NIH HHS P50 AG005142NIA NIH HHS R01 AG031563NIA NIH HHS R01 AG034570NIA NIH HHS R01 AG042292
6 · The paper itself

Abstract

importanceBecause deposition of cerebral β-amyloid (Aβ) seems to be a key initiating event in Alzheimer disease (AD), factors associated with increased deposition are of great interest. Whether elevated serum cholesterol levels act as such a factor is unknown.

objectiveTo investigate the association between serum cholesterol levels and cerebral Aβ during life early in the AD process. DESIGN, SETTING, AND

participantsA multisite, university medical center-based, cross-sectional analysis of potential associations between contemporaneously assayed total serum cholesterol, high-density lipoprotein cholesterol (HDL-C), low-density lipoprotein cholesterol (LDL-C), and cerebral Aβ, measured with carbon C11-labeled Pittsburgh Compound B (PIB) positron emission tomography. Seventy-four persons (mean age, 78 years) were recruited via direct outreach in stroke clinics and community senior facilities following a protocol designed to obtain a cohort enriched for cerebrovascular disease and elevated vascular risk. Three patients had mild dementia. All others were clinically normal (n = 33) or had mild cognitive impairment (n = 38).

resultsCerebral Aβ was quantified using a Global PIB Index, which averages PIB retention in cortical areas prone to amyloidosis. Statistical models that controlled for age and the apolipoprotein E ε4 allele revealed independent associations among the levels of LDL-C, HDL-C, and PIB index. Higher LDL-C and lower HDL-C levels were both associated with a higher PIB index. No association was found between the total cholesterol level and PIB index. No association was found between statin use and PIB index, and controlling for cholesterol treatment in the statistical models did not alter the basic findings. CONCLUSIONS AND RELEVANCE: Elevated cerebral Aβ level was associated with cholesterol fractions in a pattern analogous to that found in coronary artery disease. This finding, in living humans, is consistent with prior autopsy reports, epidemiologic findings, and animal and in vitro work, suggesting an important role for cholesterol in Aβ processing. Because cholesterol levels are modifiable, understanding their link to Aβ deposition could potentially and eventually have an effect on retarding the pathologic cascade of AD. These findings suggest that understanding the mechanisms through which serum lipids modulate Aβ could offer new approaches to slowing Aβ deposition and thus to reducing the incidence of AD.

Indexed as

AgedAged, 80 and overAlzheimer DiseaseAmyloid beta-PeptidesAmyloidosisCerebral CortexCholesterolCohort StudiesCross-Sectional StudiesFemaleHumansMaleRadionuclide ImagingAmyloid beta-PeptidesCholesterol

Identifiers

PMID24378418
PMCPMC4083819
OpenAlexW2047972989

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.